HFS
NRIX icon

Hughes Financial Services’s Nurix Therapeutics NRIX Stock Holding History

Hughes Financial Services’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73 Hold
3
– – ﹤0.01% 1525
2026
Q1 		$47 Buy
+3
New +$50 ﹤0.01% 1464

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hughes Financial Services's NRIX Position: Q2 2026 in Review

Hughes Financial Services held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 3 shares worth $73. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

Hughes Financial Services first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Hughes Financial Services held 3 shares of Nurix Therapeutics worth $73 as of Q2 2026.
  • Hughes Financial Services left its Nurix Therapeutics share count unchanged in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #1525 holding.
  • Hughes Financial Services first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.